<- All drugs

MariTide

MARKETED

GIP-receptor antagonist + GLP-1 receptor agonist (peptide-antibody bispecific conjugate)

graded findings

effect domains

Evidence spread

High evidence 0Moderate evidence 5Low evidence 0Very low evidence 3

MariTide is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

MariTide MARKETED

Weight change Decrease

Moderate evidence

Once-monthly subcutaneous maridebart cafraglutide produced substantial weight reduction without an apparent plateau at 52 weeks in adults with obesity (no diabetes);...

Jastreboff AM et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - ... Source

Full findingOnce-monthly subcutaneous maridebart cafraglutide produced substantial weight reduction without an apparent plateau at 52 weeks in adults with obesity (no diabetes); dose-ranging.

PopulationObesity cohort, N=465 (63% female; mean age 47.9 y; mean BMI 37.9); 52 wk; phase 2 double-blind RCT; comparator placebo

Fundingindustry - Amgen

Scope limitsanimal data; human relevance uncertain; conference/abstract-level; identifier not fully verified; small sample (N~127)

Comparatorsplacebo

MariTide MARKETED

Weight change Decrease

Moderate evidence

Weight reduction in the obesity-with-type-2-diabetes cohort, lower in magnitude than the non-diabetes cohort.

Jastreboff AM et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - ... Source

PopulationObesity + T2D cohort, N=127 (42% female; mean age 55.1 y; mean BMI 36.5); 52 wk; phase 2 RCT; placebo comparator

Fundingindustry - Amgen

Scope limitsanimal data; human relevance uncertain; conference/abstract-level; identifier not fully verified; small sample (N~127)

Comparatorsplacebo

MariTide MARKETED

Weight change Decrease

Very low evidence

Maridebart cafraglutide (MariTide; formerly AMG 133) is a peptide-antibody conjugate that ANTAGONISES the GIP receptor while AGONISING the GLP-1 receptor; half-life...

Amgen, Phase 2 MariTide presented at ADA 85th Scientific Sessions 2025; earlier topline N... Source

Full findingMaridebart cafraglutide (MariTide; formerly AMG 133) is a peptide-antibody conjugate that ANTAGONISES the GIP receptor while AGONISING the GLP-1 receptor; half-life ~21 days. In phase 2 (NEJM 2025), mean weight change at 52 weeks was -12.3% to -16.2% in obesity without T2D (vs -2.5% placebo) and -8.4% to -12.3% in T2D (vs -1.7% placebo) on the treatment-policy (ITT) estimand, with weight loss not plateaued by 52 weeks. HbA1c fell 1.2 to 1.6 percentage points in the T2D cohort.

PopulationPhase 2 (NCT05669599): N=592. Cohort A obesity no T2D (n=465); Cohort B obesity with T2D (n=127). Monthly fixed doses 140/280/420 mg + 8-week 420 mg arm vs placebo; 52 wk

Fundingindustry (company press release on own pipeline)

Scope limitsconference/abstract-level

Comparatorsplacebo

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

MariTide MARKETED

Pharmacology and mechanism Not directional

Moderate evidence

Long-acting peptide-antibody (anti-GIPR monoclonal antibody) conjugate combining GLP-1R agonism with GIPR antagonism; supports once-monthly (q4w) and tested q8w dosing.

Jastreboff AM et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - ... Source

PopulationMechanistic/PK description; phase 2

Fundingindustry - Amgen

Scope limitsanimal data; human relevance uncertain; conference/abstract-level; identifier not fully verified; small sample (N~127)

MariTide MARKETED

Pharmacology and mechanism Mixed

Very low evidence

Rodent mechanistic comparison: GIPR agonism vs antagonism produce distinct metabolic profiles despite both lowering weight in obese mice.

Davies I et al. A metabolic comparison of GIPR agonism versus GIPR antagonism in male mic... Source

PopulationLean and high-fat-diet obese male mice; preclinical

Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)

Scope limitsanimal data; human relevance uncertain

ComparatorsGIPR agonist GIP108; GIPR antagonist NN-GIPR-Ant; pair-fed controls

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

MariTide MARKETED

Body composition Decrease

Very low evidence

Most weight lost attributed to fat mass; body composition improved (company-reported at ADA 2025).

Amgen press release: Results from Amgen's phase 2 obesity study of monthly MariTide prese... Source

PopulationPhase 2 obesity cohorts; 52 wk; placebo comparator

Fundingindustry - Amgen

Scope limitsconference/abstract-level; identifier not fully verified

Comparatorsplacebo

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

MariTide MARKETED

Glycaemic control Decrease

Moderate evidence

HbA1c reduction in the obesity + T2D cohort.

Jastreboff AM et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - ... Source

PopulationObesity + T2D cohort, N=127; 52 wk; phase 2 RCT; placebo comparator

Fundingindustry - Amgen

Scope limitsanimal data; human relevance uncertain; conference/abstract-level; identifier not fully verified; small sample (N~127)

Comparatorsplacebo

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

MariTide MARKETED

Gastrointestinal tolerability Increase

Moderate evidence

Gastrointestinal adverse events common but mitigated by lower starting dose and dose escalation.

Jastreboff AM et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - ... Source

PopulationFull phase 2 population N=592; 52 wk; placebo comparator

Fundingindustry - Amgen

Scope limitsanimal data; human relevance uncertain; conference/abstract-level; identifier not fully verified; small sample (N~127)

Comparatorsplacebo